Hanmi Science Co., Ltd.

Hanmi Pharm. Co., Ltd.

Hanmi Holdings Co., Ltd.

Hanmi Pharmaceutical Co., Ltd.

Hammi Holdings Co., Ltd

Hanmi Science

Gwan Sun Lee

Se Chang Kwon

Sung Youb Jung

Dae Hae Song

Young Hoon Kim

Young-Kil Chang

Jin Sun Kim

Han Kyong Kim

Tae Hee Ha

Jaeheon Lee

Young Min Kim

Eun Young Kim

Kwee Hyun Suh

Chang Ki Lim

Maeng Sup Kim

Young Kil Chang

In Young Choi

Sung Min Bae

Chang Hee Park

Young Ho Moon

Won Jeoung Kim

Hee Sook Oh

Sung H Hong

Young Jin Park

Chang Hwan Kim

Dae Jin Kim

Gha-Seung Park

Eun Sook Kim

Mi Young Cha

Jong Woo Kim

Ji Eun Lee

Bum Woo Park

Dong Jun Kim

Young Jin Ham

Ji Sook Kim

Kwee-Hyun Suh

Chul-Hyun Park

Jae Min Lee

Jae Chul Lee

Jae-cheol Lee

Ji Yeon Song

Young Gil Ahn

Se Young Kim

Jong Soo Woo

Jae Hee Shin

Geun Hee Yang

Mi Ji Lee

Eun Jung Lim

Jin Hee Kim

Eun-Ju Park

Keuk Chan Bang

Moon Sub Lee

Nam Du Kim

Cheol Kyung Kim

Ki-Doo Choi

Sang Min Yun

Sangmin Yun

Jae Ho Yoo

Chul Hyun Park

Moonsub Lee

Weon Ki Yang

Gha Seung Park

Tae Jin Choi

Hee Seock Kim

Young-Gil Ahn

Hyo-Jeong Bang

Kyoung Soo Kim

Min Young Kim

Hyun Ji Lee

Hyun Seung Lee

Kwang Ok Lee

Young Kyung Park

Young Hee Jung

Wan Joo Kim

Seong Hee Park

Mi Ra Kim

Jong Pil Chun

Mi Young Ko

Bo Sung Kwon

Sun Young Jung

Dong Jin Hong

Jung Hee Han

Jaeho Yoo

Cheol Hyun Park

Tae Hun Song

Jae Heon Lee

Chang In Kim

Chang Ju Choi

Hyo Jeong Bang

Yoon Ju Lee

Choong-Hahn Kim

Suk Man Jang

Eun Hee Kang

Jae Hyuk Jung

Kyung Ik Lee

Kwang-Ok Lee

Disclosed is an IgG Fc fragment useful as a drug carrier. A recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment are disclosed. When conjugated to a certain drug, the IgG Fc fragment improves the in vivo duration of action of the drug and minimizes the in vivo activity reduction of the drug.

IgG Fc fragment for a drug carrier and method for the preparation thereof

Disclosed is a protein complex, comprising a physiologically active polypeptide, a dimeric protein and a non-peptidyl polymer having three functional ends (3-arm), with the linkage of both the physiologically active polypeptide and the dimeric protein to the 3-arm non-peptidyl polymer via respective covalent bonds. The protein complex guarantees the long acting activity and biostability of a physiologically active polypeptide. Having the ability to maintain the bioactivity of physiologically active polypeptides or peptides highly and to significantly improve the serum half life of the polypeptides or peptides, the protein complex can be applied to the development of sustained release formulations of various physiologically active polypeptide drugs. Also, it utilizes raw materials including the physiologically active polypeptides without significant loss, thereby increasing the production yield. Further, it can be easily purified.

Polypeptide complex comprising non-peptidyl polymer having three functional ends

Disclosed are a protein conjugate with improved in vivo duration and stability and the use thereof. The protein conjugate includes a physiologically active polypeptide, a non-peptide polymer and an immunoglobulin Fc fragment. Since the three components are covalently linked, the protein conjugate has extended in vivo duration and enhanced stability for the physiologically active polypeptide. The protein conjugate maintains the in vivo activity at relatively high levels and remarkably increases the serum half-life for the physiologically active polypeptide, with less risk of inducing undesirable immune responses. Thus, the protein conjugate is useful for developing long-acting formulations of various polypeptide drugs.

Protein complex using an immunoglobulin fragment and method for the preparation thereof

The present invention relates to an N-terminal amino acid-modified insulinotropic peptide having a high activity, and to a pharmaceutical composition comprising the same. The insulinotropic peptide derivatives according to the present invention exhibit therapeutic effects, which are not observed in native and other insulinotropic peptide analogs. Therefore, the insulinotropic peptide derivatives and the pharmaceutical composition comprising the same according to the present invention can be effectively provided for the treatment of the diseases.

N-terminal modified exendin-4

Disclosed herein is an inducible high-expression cassette comprising a dihydrofolate reductase (DHFR) promoter from which GC-rich repeat sequences are partially or entirely removed, the cassette capable of more effectively improving a gene amplification system. Also disclosed are an expression vector comprising the inducible expression cassette and optionally a gene encoding a recombinant protein of interest, an animal cell line transformed with the expression vector, and a method of mass producing and purifying a recombinant protein by culturing the transformant. The present invention enables the shortening of the time required to establish a cell line producing a recombinant protein of interest at high levels using a low concentration of a DHFR inhibitor, thereby allowing more effective production of the recombinant protein.

Vector and expression cell line for mass production of recombinant protein and a process of producing recombinant protein using same

The present invention provides a method for preparing a site-specific physiologically active polypeptide conjugate in a high yield by treating a physiologically active polypeptide with a non-peptidyl polymer in the presence of an alcohol at a specific pH, which can be desirably employed in the development of long acting formulations of various peptide drugs having high in-vivo activity and markedly prolonged in-blood half-life.

Method for preparing a site-specific physiologically active polypeptide conjugate

Disclosed is an IgG Fc fragment useful as a drug carrier. Also, the present invention discloses a recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment, comprising culturing the transformant. When conjugated to a certain drug, the IgG Fc fragment improves the in vivo duration of action of the drug and minimizes the in vivo activity reduction of the drug.

The present invention relates to a novel quinazoline derivative compound having the formula (1) as follows: with the constituents defined in claim, and a pharmaceutically acceptable salt thereof as a multiplex inhibitor, a method for the preparation thereof, and a pharmaceutical composition and a therapeutic composition comprising same as an active ingredient. The inventive quinazoline derivative as a multiplex inhibitor can selectively and effectively inhibit diseases caused by the overactivity of a tyrosine kinase.

Quinazoline derivatives as a multiplex inhibitor and method for the preparation thereof

Disclosed are a recombinant expression vector comprising a nucleotide sequence encoding an-derived signal sequence and a nucleotide sequence encoding an immunoglobulin constant region, and a transformant transformed with the expression vector. Also, disclosed is a method of mass-producing an immunoglobulin constant region by culturing the transformant and expressing the immunoglobulin constant region in a water-soluble form.

Method for the mass production of immunoglobulin constant region

The present invention relates to a high-yield method for preparing highly pure (3S,4S)-4-((R)-2-(benzyloxy)tridecyl)-3-hexyl-2-oxetanone using a metal salt of (2S,3S,5R)-2-hexyl-3,5-dihydroxyhexadecanoic acid as an intermediate.

Method for preparing (3S,4S)-4-((R)-2-(benzyloxy)tridecyl)-3-hexyl-2-oxetanone and novel intermediate used therefor

Disclosed are a novel, simple and low-cost method for preparing sitagliptin of formula (I), as DPP-IV (dipeptidyl peptidase IV) inhibitor, which is useful in treating type 2 diabetes mellitus and key intermediates used in said preparation of sitagliptin: 

Method of preparing sitagliptin and intermediates used therein

Growing community of inventors

Seoul, South Korea

Gwan Sun Lee